NASDAQ · Biotechnology

ALKS (ALKS) Stock

$47.20 +0.45% NASDAQ: ALKS Healthcare

Valuation

MetricValue
Price$47.20
Market Cap$7.92B
P/E Ratio25.87
P/B Ratio3.39
P/S Ratio4.11
EPS (TTM)$1.43
52-Week High$55.54
52-Week Low$25.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE13.30%
ROA9.57%
ROCE13.96%
Gross Margin17.21%
Operating Margin17.21%
Net Margin9.78%
Debt/Equity0.90
Current Ratio3.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.2B$1.1B$1.7B$1.6B$1.5B
Operating Profit$98.0M$-6.0M$414.0M$421.0M$254.0M
Net Profit$-48.0M$-158.0M$356.0M$367.0M$242.0M
EPS$-0.30$-0.97$2.10$2.17$1.43
Op Margin8.3%-0.6%24.9%27.0%17.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.0B$2.0B$2.1B$2.1B$2.5B
Total Liabilities$912.0M$920.0M$934.0M$591.0M$711.0M
Cash$338.0M$292.0M$457.0M$291.0M$1.1B
Borrowings$416.0M$379.0M$372.0M$76.0M$70.0M

Latest News

Alkermes to Report Second Quarter Financial Results on July 28, 2026 Business Wire · Jul 14, 2026 American Express, Biogen upgraded: Wall Street's top analyst calls The Fly · Jul 13, 2026 Alkermes Public's Alixorexton Demonstrates Durable Efficacy in Narcolepsy Patients MT Newswires · Jul 13, 2026 Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis Business Wire · Jul 13, 2026 Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar? Zacks · Jul 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$102.0M$21.0M$401.0M$439.0M$521.0M
Investing Cash Flow$-95.0M$-103.0M$5.0M$-145.0M$255.0M
Financing Cash Flow$-17.0M$-18.0M$-303.0M$-202.0M$-31.0M
Net Cash Flow$65.0M$-45.0M$165.0M$-166.0M$829.0M
Free Cash Flow$73.0M$-17.0M$353.0M$406.0M$480.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA18.21
FCF Yield7.78%
Quick Ratio3.19
Interest Coverage21.17
Return 1Y63.88%
Return 3Y74.43%
Return 5Y58.02%

Ownership

Insiders Held1.43%
Institutions Held110.67%
Institutions Float Held112.27%
Institutional HolderSharesReport Date
Blackrock Inc.28,314,4102026-03-31
Baker Bros. Advisors, LP10,012,2672026-03-31
Vanguard Portfolio Management LLC9,511,1122026-03-31
State Street Corporation9,465,2862026-03-31
Vanguard Capital Management LLC7,427,3972026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $28.89 -0.07% 8.94 $4.95B 0.00%
ACLXArcellx, Inc. $115.07 +0.02% -28.27 $6.73B 0.00%
AKROAkero Therapeutics, Inc. $54.65 +0.00% -19.87 $4.50B 0.00%
ARWR $82.74 +0.42% -7397.00 $11.65B 0.00%
CRSP $56.82 -0.28% -11.97 $5.48B 0.00%

About ALKS

ALKS is led by CEO Richard F. Pops, employs 2,050 people, headquartered in Dublin, IE, publicly traded since 1991.

ALKS stock trades at $47.20 with a market capitalization of $7.92B. The stock is valued at a price-to-earnings (P/E) ratio of 25.87, price-to-book of 3.39, price-to-sales of 4.11. Over the past 52 weeks the stock has ranged between $25.17 and $55.54, and currently trades 15.0% below its 52-week high.

On profitability, ALKS generates a return on equity (ROE) of 13.30%, above the typical market average, return on capital employed of 13.96%, an operating margin of 17.21%, a net profit margin of 9.78%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides